Literature DB >> 23422653

Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function.

Stavros Stavrakis1, Aneesh Pakala, Jimmy Thomas, Muhammad A Chaudhry, Udho Thadani.   

Abstract

BACKGROUND: An inverse relationship between brain natriuretic peptide (BNP) levels and body mass index (BMI) has been described for patients with left ventricular (LV) systolic dysfunction. In this study, the association of BMI, BNP levels and mortality in patients hospitalized for heart failure with preserved LV systolic function (HFpLVF) was investigated.
METHODS: One hundred fifty consecutive patients (98% men) who were hospitalized with HFpLVF and had BNP levels measured on admission were analyzed. Patients were divided into categories of BMI: normal (BMI < 25 kg/m), overweight (BMI 25-29.9 kg/m) and obese (BMI ≥ 30 kg/m). Relevant clinical and echocardiographic characteristics and all-cause mortality were obtained through chart review.
RESULTS: BNP levels were significantly lower in obese (median = 227 pg/mL) and overweight (median = 396 pg/mL) patients compared with those with normal BMI (median = 608 pg/mL, P = 0.003). Higher BMI predicted BNP levels of <100 pg/mL. Compared with patients with normal BMI, overweight and obese patients had a significantly lower risk of total mortality, even after adjusting for other clinical characteristics, including log-transformed BNP levels, atrial fibrillation, the use of beta-blockers at discharge, age, hemoglobin levels and the presence of pulmonary congestion on admission. Higher BNP levels also independently predicted mortality.
CONCLUSIONS: An inverse relationship between BMI and BNP levels exists in patients hospitalized with HFpLVF. Higher BMI is associated with lower mortality, whereas higher BNP levels predict higher mortality in male patients with HFpLVF. These findings should be confirmed in a larger multicenter setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23422653     DOI: 10.1097/MAJ.0b013e318271c012

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  10 in total

Review 1.  Patient selection in heart failure with preserved ejection fraction clinical trials.

Authors:  Jacob P Kelly; Robert J Mentz; Alexandre Mebazaa; Adriaan A Voors; Javed Butler; Lothar Roessig; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor; Carolyn S P Lam
Journal:  J Am Coll Cardiol       Date:  2015-04-28       Impact factor: 24.094

Review 2.  Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Bharathi Upadhya; Barbara Pisani; Dalane W Kitzman
Journal:  J Am Geriatr Soc       Date:  2017-11       Impact factor: 5.562

Review 3.  Molecular Mechanism of Induction of Bone Growth by the C-Type Natriuretic Peptide.

Authors:  Estera Rintz; Grzegorz Węgrzyn; Toshihito Fujii; Shunji Tomatsu
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

4.  Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Authors:  Dalane W Kitzman; Peter Brubaker; Timothy Morgan; Mark Haykowsky; Gregory Hundley; William E Kraus; Joel Eggebeen; Barbara J Nicklas
Journal:  JAMA       Date:  2016-01-05       Impact factor: 56.272

Review 5.  INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist.

Authors:  Hugo R Ramos; Andreas L Birkenfeld; Adolfo J de Bold
Journal:  Endocr Connect       Date:  2015-09       Impact factor: 3.335

Review 6.  Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales.

Authors:  Albin Oh; Ross Okazaki; Flora Sam; Maria Valero-Muñoz
Journal:  Front Cardiovasc Med       Date:  2019-08-02

Review 7.  Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF).

Authors:  Emmanuel Eroume A Egom
Journal:  Front Physiol       Date:  2021-05-21       Impact factor: 4.566

8.  Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial.

Authors:  Ambarish Pandey; Jarett D Berry; Mark H Drazner; James C Fang; W H Wilson Tang; Justin L Grodin
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

9.  Natriuretic peptides for the detection of diastolic dysfunction and heart failure with preserved ejection fraction-a systematic review and meta-analysis.

Authors:  Sharon Remmelzwaal; Adriana J van Ballegooijen; Linda J Schoonmade; Elisa Dal Canto; M Louis Handoko; Michiel T H M Henkens; Vanessa van Empel; Stephane R B Heymans; Joline W J Beulens
Journal:  BMC Med       Date:  2020-10-30       Impact factor: 8.775

10.  Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.

Authors:  Joban Vaishnav; Jessica E Chasler; Yizhen J Lee; Chiadi E Ndumele; Jiun-Ruey Hu; Steven P Schulman; Stuart D Russell; Kavita Sharma
Journal:  J Am Heart Assoc       Date:  2020-07-30       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.